06:02 PM EDT, 05/23/2024 (MT Newswires) -- Zentalis Pharmaceuticals ( ZNTL ) said final results from a phase 1 trial of azenosertib plus gemcitabine in relapsed or refractory osteosarcoma resulted in clinically meaningful increase in event-free survival compared to historical comparators.

The company said the combination was also well tolerated, supporting further evaluation through a mid-stage trial.

"Azenosertib provides promise as a novel class of drugs and offers hope for a well-tolerated and potentially efficacious treatment option that is desperately needed," said Viswatej Avutu, Sarcoma Medical Oncology Service and Pediatric Sarcoma Team of Memorial Sloan Kettering Cancer Center in New York.

The results will be presented at the 2024 American Society of Clinical Oncology annual meeting in Chicago.

Price: 11.30, Change: +0.02, Percent Change: +0.18